Evidence Repository
The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • See Evidence submitted by expert panel for details.

Variant: NM_001754.4(RUNX1):c.602G>A (p.Arg201Gln)

CA248610

14464 (ClinVar)

Gene: RUNX1
Condition: hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome
Inheritance Mode: Autosomal dominant inheritance
Link to MONDO
UUID: 52b9ca56-4641-4652-8c86-bee9650bacf2
Approved on: 2019-07-30
Published on: 2019-08-02

HGVS expressions

NM_001754.4:c.602G>A
NM_001754.4(RUNX1):c.602G>A (p.Arg201Gln)
NC_000021.9:g.34859485C>T
CM000683.2:g.34859485C>T
NC_000021.8:g.36231782C>T
CM000683.1:g.36231782C>T
NC_000021.7:g.35153652C>T
NG_011402.2:g.1130227G>A
ENST00000675419.1:c.602G>A
ENST00000300305.7:c.602G>A
ENST00000344691.8:c.521G>A
ENST00000358356.9:c.521G>A
ENST00000399237.6:c.566G>A
ENST00000399240.5:c.521G>A
ENST00000437180.5:c.602G>A
ENST00000467577.1:n.94G>A
ENST00000482318.5:c.*192G>A
NM_001001890.2:c.521G>A
NM_001122607.1:c.521G>A
NM_001001890.3:c.521G>A
NM_001122607.2:c.521G>A
NM_001754.5:c.602G>A
More

Pathogenic

Met criteria codes 6
PM1 PM2 PS3 PS4 PP1 PP3
Not Met criteria codes 20
PVS1 PM3 PM5 PM4 PM6 BA1 BS2 BS1 BS4 BS3 BP4 BP3 BP1 BP2 BP5 BP7 PS1 PS2 PP2 PP4

Evidence Links 9

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Myeloid Malignancy VCEP
Transactivation assays demonstrate altered transactivation (<20% of wt) for the NM_001754.4:c.602G>A (p.Arg201Gln) variant and data from a secondary assays demonstrate altered DNA binding, CBFβ binding and sub-cellular localization (PS3; PMID: 17290219, 11830488, 23817177, 22318203, 25840971, 23848403). This variant has been reported in four probands meeting at least one of the RUNX1-phenotypic criteria (PS4; PMID: 27112265, 28748566, 10508512). This variant affects one of the hotspot residues established by the MM-VCEP for RUNX1 (PM1). It is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). The variant has a REVEL score >0.75 (0.94) (PP3). It was found to co-segregate with disease in multiple affected family members, with four meioses observed in across 3 families (PP1; PMID: 27112265, 28748566, 10508512). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PS4, PM1, PM2, PP1, PP3.
Met criteria codes
PM1
Residue that affects DNA binding and is a somatic hot spot as a mutational hot spot.
PM2
The variant is absent from all population databases.
PS3
Transactivation assays demonstrate altered transactivation (<20% of WT). Secondary assays demonstrate altered DNA binding, CBFβ binding and sub-cellular localization.
Transactivation assays demonstrate altered transactivation (<20% of WT). Secondary assays demonstrate altered DNA binding, CBFβ binding and sub-cellular localization. PubMed:23848403
Transactivation assays demonstrate altered transactivation (<20% of WT). Secondary assays demonstrate altered DNA binding, CBFβ binding and sub-cellular localization. PubMed:11830488
Transactivation assays demonstrate altered transactivation (<20% of WT). Secondary assay demonstrate altered sub-cellular localization. PubMed:23817177
The number of CFU-C in R174Q/+ AGM regions was reduced slightly more than in DelE4/+ fetuses, suggesting that the R174Q mutation creates a weakly dominant-negative Runx1 allele. R174Q/+ mice had a smaller percentage of CD4 + cells and a lower CD4 + : CD8 + ratio than DelE4/ + animals. PubMed:17290219
Transactivation assays demonstrate altered transactivation (<20% of WT). Secondary assays demonstrate altered DNA binding and sub-cellular localization. PubMed:22318203
Transactivation assays demonstrate altered transactivation (<20% of WT). Secondary assay demonstrate altered DNA binding. PubMed:25840971
PS4
4 probands counted across publications.
1 proband with secondary AML to MDS. PubMed:27112265
1 proband (Patient 64) with lifelong history of severe thrombocytopenia and bleeding tendency. She developed myelodysplasia when aged 65 years and 1 proband with chronic thrombocytopenia. PubMed:28748566
1 proband with thrombocytopenia and leukemia PubMed:10508512
PP1
4 segregations counted additively across publications
2 segregations - 3 individuals with chronic thrombocytopenia, no MDS PubMed:28748566
Pedigree C, family also reported in PMID: 22898599 and PMID: 23692290 (Family A) - 4 affected individuals meeting phenotype criteria, but unclear whether all were genotyped. Counting only the two individuals explicitly stated to have been genotyped. PubMed:27112265
1 segregation - 2 affected individuals with thrombocytopenia and leukemia PubMed:10508512
PP3
REVEL: 0.94 >0.75
Not Met criteria codes
PVS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM5
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM6
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BA1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS4
2 segregations - 3 individuals with chronic thrombocytopenia, no MDS PubMed:28748566
Pedigree C, family also reported in PMID: 22898599 and PMID: 23692290 (Family A) - 4 affected individuals meeting phenotype criteria, but unclear whether all were genotyped. Counting only the two individuals explicitly stated to have been genotyped. PubMed:27112265
1 segregation - 2 affected individuals with thrombocytopenia and leukemia PubMed:10508512
BS3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP5
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP7
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.